Detection of Overlooked Rare <scp><i>EGFR</i></scp> Mutations in Non‐small Cell Lung Cancer Using Multigene Testing
ODxTT failed to identify 10 actionable EGFR mutations, accounting for 12.2% (10/82) of the cases initially reported as not carrying actionable mutations. Therefore, comprehensive genomic profiling should be actively performed early in cases with high clinical suspicion of EGFR mutations.
Authors
- Kazuto Nishio (ORCID: https://orcid.org/0000-0002-8275-0846)
- Kazuko Sakai (ORCID: https://orcid.org/0000-0003-1822-2720)
- Chiaki Inagaki (ORCID: https://orcid.org/0000-0003-1282-232X)
- Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0001-8787-5587)
- Kimio Yonesaka (ORCID: https://orcid.org/0000-0002-0816-5315)
- Hiroaki Kanemura (ORCID: https://orcid.org/0000-0002-0858-8107)
- Tsutomu Iwasa (ORCID: https://orcid.org/0000-0001-5996-0602)
- Yusuke Kawanaka (ORCID: https://orcid.org/0000-0001-8494-4970)
- Kazuhiko Nakagawa
- Takayuki Takahama (ORCID: https://orcid.org/0000-0002-0321-6718)
- Junko Tanizaki (ORCID: https://orcid.org/0000-0002-6727-9435)
- Tetsuya Mitsudomi (ORCID: https://orcid.org/0000-0001-9860-8505)
- Shinichiro Suzuki
- Kaoru Tanaka (ORCID: https://orcid.org/0000-0002-4927-1368)
- Tomohiro Nakayama
- Takashi Kurosaki
- Kazuya Fukuoka
- Yuzuki Nakagawa
- N. Shiraishi
Institutions
- Kindai University Hospital (JP)
- Kishiwada City Hospital (JP)
- Izumi City General Hospital (JP)
- Kindai University (JP)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/1759-7714.70007
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Boehringer Ingelheim Japan
- Kanazawa University
- Otsuka Pharmaceutical
- Yakult Honsha
- SymBio Pharmaceuticals Limited
- Novartis Pharma
- Pfizer Japan
- Chugai Pharmaceutical
- Eli Lilly Japan
- Daiichi Sankyo Europe